---
schema_version: "secwatch.filing_event.v1"
accession: "0001390478-24-000011"
form_type: "8-K"
ticker: "SLS"
cik: "0001390478"
company_name: "SELLAS Life Sciences Group, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:32:54.979049+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# SELLAS Q1 net loss $9.6M; Phase 2 SLS009 100% response in ASXL1 AML; IDMC backs REGAL trial

## Summary
- Net loss of $9.6M ($0.21/share) vs $11.1M ($0.47/share) in Q1 2023.
- Cash and equivalents $18.4M at March 31, 2024; R&D expense $5.1M, G&A $4.5M.
- IDMC recommends continue Phase 3 REGAL (GPS in AML) without modification; next review June 2024 of all 127 patients.
- SLS009 Phase 2: 62% anti-leukemic activity all doses, 67% at 30mg BIW; 100% ORR in ASXL1 mutation patients at 30mg BIW; cohort expanding.
- Phase 3 REGAL enrollment completed; provisional patent filed for SLS009 in ASXL1-mutated AML.

## SEC filing metadata
- accession: 0001390478-24-000011
- form_type: 8-K
- ticker: SLS
- cik: 0001390478
- company_name: SELLAS Life Sciences Group, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1390478/000139047824000011/0001390478-24-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1390478/000139047824000011/sls-20240514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001390478-24-000011
- JSON: https://secwatch.observer/filing/0001390478-24-000011.json
- Plain text: https://secwatch.observer/filing/0001390478-24-000011.txt

## Key facts
- Earnings Releases
  SELLAS Life Sciences Group, Inc. reported the first quarter ended March 31, 2024 results: net income $9.6 million, EPS $0.21.
  - Period: the first quarter ended March 31, 2024
  - Net income: $9.6 million
  - EPS: $0.21
  - Result: reported results
  source text: SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update
  evidence_url: https://www.sec.gov/Archives/edgar/data/1390478/000139047824000011/0001390478-24-000011-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.